Identification of a New Class of Antifungals Targeting the Synthesis of Fungal Sphingolipids

Recent estimates suggest that>300 million people are afflicted by serious fungal infections worldwide. Currentantifungal drugs are static and toxic and/or have a narrow spectrum of activity. Thus, there is an urgent need for the development of newantifungal drugs. The fungal sphingolipid glucosylceramide (GlcCer) is critical in promoting virulence of a variety of human-pathogenic fungi.
Source: The Aspergillus Website - updates - Category: Respiratory Medicine Authors: Source Type: news